Expertise
Early and Late Clinical Stage Commercial Strategy
Oncology Solid Tumors
Platinum Resistant Ovarian Cancer
Clear Cell Renal Cell Carcinoma
Pancreatic Adenocarcinoma
Non-Small Cell Lung Cancer
Head & Neck Squamous Cell Carcinoma
Metastatic Colorectal Cancer
Oncology Liquid Tumors
Non-Hodgkin’s Lymphoma
Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Acute Myeloid Lymphoma
Proximal Nocturnal Hemoglobinuria (PNH)
Multiple Myeloma
Other Disease Areas
Epidermolysis Bullosa
CNS Major Depression Disorder/Anxiety, Eating Disorders
Endometriosis and Uterine Fibroids
Anaphylaxis/Envenomation
Moderate to Severe Asthma
Neovascular Age - Related Macular Degeneration
Plaque Psoriasis
Status Epilepticus
Product Launches
Company’s First Product Launch
Platinum Resistant Ovarian Cancer
DLBCL – Antibody Drug Conjugate
Pediatric Low-Grade Glioma (pLGG)
Osteoporosis – First Biologic
Non-Muscle Invasive Bladder Cancer
Hypercholesterolemia – Small Molecule, Combination Therapy
Primary IgA Nephropathy - First in the Disease Area
Other Significant Launches
Epidermolysis Bullosa – Indication Expansion
CNS Migraine – Global Launch Strategy Including Ground-Breaking Advocacy Program
Osteoporosis & Bone Metastasis
Melanoma – First and Only Oncolytic Virus US and Global Launch
Paroxysmal Nocturnal Hemoglobinuria – Global Launch
Rheumatoid Arthritis - Relaunch
Post Launch LCM, Market Expansion, Competitive Entry Strategy
Cancer Treatment Supportive Care – Novel Drug Delivery System
Rheumatoid Arthritis – Disease Area Expansion to Psoriatic Arthritis, Ankylosing
Psoriasis - Launch Preparation
Wound Management – OTC Ointment, Development of 510k & ODD Pathway
Multiple Myeloma – Global Lifecycle Management and Strategy
Hyperuricemia – Patient Support Services
Cataplexy and Excessive Sleepiness in Narcolepsy – Patient Support Services
Breast Cancer – Market Expansion